If there’s one good thing that’s come from the pandemic, it’s this: Scientists and drug manufacturers came together in record time and with a shared purpose to create a safe and effective Covid-19 vaccine. In doing so, they set a precedent for medical advancements. So, where do we go from here? In this episode, we’ll talk about how biopharma companies can learn from last year’s disruption and harness what Accenture calls ‘New Science’ to rapidly discover and deliver revolutionary treatments and preparing for in the midst of regulatory and economic shifts. We’ll speak with Chris Gibson, C.E.O. and Co-Founder at Recursion; Stuart Henderson, Global Industry Lead — Life Sciences at Accenture; and David Coman, C.E.O at Science 37.

This week's guests: 

Chris Gibson, C.E.O. and Co-Founder at Recursion

Stuart Henderson, Global Industry Lead — Life Sciences at Accenture

David Coman, C.E.O at Science 37